Revenues

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenues

REVENUES

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):

	Three Months Ended March 31, 2019								Three Months Ended March 31, 2018
	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
Atripla	$	133	$	16	$	22	$	171	$	228	$	51	$	35	$	314
Biktarvy	739		48		6		793		35		—		—		35
Complera/Eviplera	44		62		9		115		67		109		14		190
Descovy	233		68		41		342		274		75		12		361
Genvoya	728		193		94		1,015		853		186		43		1,082
Odefsey	282		106		9		397		279		58		5		342
Stribild	67		18		11		96		133		29		12		174
Truvada	551		33		22		606		507		97		48		652
Other HIV(1)	11		1		5		17		9		1		3		13
Revenue share – Symtuza(2)	42		24		—		66		—		7		—		7
AmBisome	8		57		28		93		17		56		34		107
Ledipasvir/Sofosbuvir(3)	117		27		81		225		234		56		58		348
Letairis	197		—		—		197		204		—		—		204
Ranexa	155		—		—		155		195		—		—		195
Sofosbuvir/Velpatasvir(4)	230		154		107		491		269		198		69		536
Vemlidy	65		4		32		101		47		3		8		58
Viread	12		14		46		72		7		30		60		97
Vosevi	45		16		2		63		86		16		5		107
Yescarta	90		6		—		96		40		—		—		40
Zydelig	11		15		1		27		14		18		1		33
Other(5)	36		20		6		62		29		15		62		106
Total product sales	3,796		882		522		5,200		3,527		1,005		469		5,001
Royalty, contract and other revenues	22		56		3		81		20		52		15		87
Total revenues	$	3,818	$	938	$	525	$	5,281	$	3,547	$	1,057	$	484	$	5,088

____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen)
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5)	Includes Cayston, Hepsera and Sovaldi

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

During the three months ended March 31, 2019 and 2018, revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $155 million and $97 million, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $107 million increase and $87 million decrease in revenues during the three months ended March 31, 2019 and 2018, respectively.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $140 million and $125 million as of March 31, 2019 and December 31, 2018, respectively.

Contract liabilities were not material as of March 31, 2019 and December 31, 2018.